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Abstract
Background: Facioscapulohumeral dystrophy (FSHD) is commonly associated with contraction of the D4Z4
macro-satellite repeat on chromosome 4q35 (FSHD1) or mutations in the SMCHD1 gene (FSHD2). Recent studies
have shown that the clinical manifestation of FSHD1 can be modified by mutations in the SMCHD1 gene within a
given family. The absence of either D4Z4 contraction or SMCHD1 mutations in a small cohort of patients suggests
that the disease could also be due to disruption of gene regulation. In this study, we postulated that mutations
responsible for exerting a modifier effect on FSHD might reside within remotely acting regulatory elements that
have the potential to interact at a distance with their cognate gene promoter via chromatin looping. To explore
this postulate, genome-wide Hi-C data were used to identify genomic fragments displaying the strongest
interaction with the SMCHD1 gene. These fragments were then narrowed down to shorter regions using ENCODE
and FANTOM data on transcription factor binding sites and epigenetic marks characteristic of promoters,
enhancers and silencers.
Results: We identified two regions, located respectively ~14 and ~85 kb upstream of the SMCHD1 gene, which
were then sequenced in 229 FSHD/FSHD-like patients (200 with D4Z4 repeat units <11). Three heterozygous
sequence variants were found ~14 kb upstream of the SMCHD1 gene. One of these variants was found to be of
potential functional significance based on DNA methylation analysis. Further functional ascertainment will be
required in order to establish the clinical/functional significance of the variants found.
Conclusions: In this study, we propose an improved approach to predict the possible locations of remotely
acting regulatory elements that might influence the transcriptional regulation of their associated gene(s). It
represents a new way to screen for disease-relevant mutations beyond the immediate vicinity of the specific
disease gene. It promises to be useful for investigating disorders in which mutations could occur in remotely
acting regulatory elements.
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Background
Facioscapulohumeral muscular dystrophy (FSHD) is the
most prevalent of the nine primary types of muscular
dystrophy affecting adults and children; it is character-
ized by the weakness and atrophy of the facial and
shoulder girdle muscle extending to the abdominal and
lower limb muscle [1]. Two genetic loci are associated
with the disease. The FSHD1 locus maps to 4q35 [2]
and accounts for 95 % of clinical diseases in an FSHD
context [1, 3]. A second FSHD locus, FSHD2, exists and
is phenotypically indistinguishable from FSHD1 [2].
FSHD1 patients harbour a large deletion in the poly-
morphic D4Z4 macro-satellite repeat array at 4q35 and
invariably present with 1–10 repeats whereas non-
affected individuals possess 11–150 repeats. Each 3.3-kb
D4Z4 unit contains a double homeobox 4 (DUX4) gene
that, among others, is transcriptionally activated on
contraction of the 4q35 repeat array as a consequence
of the induction of chromatin remodelling of the 4qter
region. A number of 4q subtelomeric sequence variants
are now recognized, although FSHD1 only occurs in as-
sociation with ‘permissive’ haplotypes, each of which is
associated with a polyadenylation signal located imme-
diately distal of the last D4Z4 unit [4]. Approximately
5 % of FSHD patients lack a contraction of the D4Z4
array, and the disease aetiology has been ascribed to a
putative FSHD2 locus. Whole-exome sequencing iden-
tified the SMCHD1 gene as the causative agent at the
FSHD2 locus [5]. In FSHD2 families, the disease ex-
hibits a more complex digenic inheritance because mu-
tations in the chromosome-18-located SMCHD1 gene
segregate independently from the FSHD-permissive 4q
haplotype [5]. SMCHD1 is a member of a condensing/
cohesion family of chromatin compact complexes that
bind to the D4Z4 array [6]. However, not all FSHD2 pa-
tients can be explained by the lack of contraction of the
D4Z4 repeats or mutations in the SMCHD1 gene, sug-
gesting either that mutations may reside within the
SMCHD1 non-coding region or that the cause of FSHD
in these families could be linked to yet another FSHD
locus. Although FSHD1 and FSHD2 are characterized
by different underlying genetic defects, they both ap-
pear to be caused by transcriptional de-repression of
DUX4 in the skeletal muscle [7].
DNA methylation changes the conformation of the
chromatin and hence the accessibility of the encoded
gene(s) in the vicinity. Hypermethylation generally
leads to the compaction of chromatin, thereby reducing
gene expression. Conversely, hypomethylation generally
serves to relax the chromatin thereby upregulating gene
expression. FSHD-affected individuals display hypome-
thylation at D4Z4 units, whereas unaffected subjects
exhibit hypermethylation whilst FSHD non-manifesting
carriers have an intermediate level of methylation [8].
The specific loss of histone H3 lysine 9 trimethylation
and HP1 gamma/cohesion binding at D4Z4 repeats is
reported to be associated with FSHD [6].
Recent studies have reported that the clinical manifest-
ation of FSHD1 can be modified by mutations in the
SMCHD1 gene within a given family [9–11] although
pathogenic FSHD mutations remained undetected in a
majority of FSHD2 patients. The undetected mutations
in such patients could, in principle, reside within regula-
tory elements, possibly at some distance from the
SMCHD1 gene, disrupting regulation of the gene.
Advances in techniques for capturing three-dimensional
chromosome conformations (3C) have been prompted by
the view that direct long-range interactions occur between
gene promoters and distal genomic regions, bringing them
into close spatial proximity through looping interactions
[12], thereby explaining the impact of pathological mu-
tations that are known to occur at some considerable
distance from the genes whose function they influence
[13]. Genome-wide mapping of long-range interactions
using the Hi-C [14], the recently proposed in situ Hi-C
[15] and Capture Hi-C [16] methods has made it pos-
sible to assess the propensity of genomic regions to
form looping interactions by surveying their interaction
frequencies; the latter two methods have yielded inter-
action maps of sufficiently high resolution to be prac-
tically useful in this regard.
Studies of the long-range interactions of ~22,000 pro-
moters in two human blood cell lines, including lympho-
blastoid cell line GM12878, employing the Capture Hi-C
method [16] have revealed that interacting fragments are
enriched in DNaseI hypersensitive sites (DHSs), a classical
marker of regulatory regions [17]; the H3K4me3 histone
mark, the tri-methylation of histone H3 at lysine 4,
mainly associated with promoters that are active or
poised to be activated ([18], reviewed in [19]); the
H3K4me1 histone mark, the mono-methylation of
histone H3 at lysine 4, a well-established feature of
enhancers and promoters; and the H3K27ac mark, the
acetylation of histone H3 at lysine 27, characteristic of
active enhancers ([18], reviewed in [19]).
In this study, we postulated that mutations responsible
for the clinical manifestation of FSHD or playing a
disease-modifier role might reside within remotely act-
ing regulatory elements that have the potential to inter-
act with the DNA fragment containing the SMCHD1
gene and that these elements might be located within
regions enriched in epigenetic features characteristic of
regulatory regions. We identified two remotely located
putative regulatory elements residing within regions re-
spectively strongly and weakly interacting with the frag-
ment containing the SMCHD1 gene. We screened these
in silico-predicted regulatory regions for mutations in
229 FSHD patients (200 patients exhibiting <11 D4Z4
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repeat units and 29 patients >11 D4Z4 repeat units). We
report two novel sequence variants in a putative control
region proximal to the SMCHD1 gene (~14 kb upstream
of the gene) in two FSHD families.
Results and discussion
In silico prediction of interacting fragments and potential
remotely acting regulatory regions of SMCHD1
Hi-C data, available at www.ncbi.nlm.nih.gov/geo/ (ac-
cession number GSE18199), indicated that a 1-Mb frag-
ment of chromosome 18, starting at position 2,000,000
and ending at position 2,999,999, which we have termed
the SMCHD1-containing fragment since it contains the
entire SMCHD1 gene (positions 2,645,885–2,795,015;
hg18), interacts most strongly with itself (3371 intra-
chromosomal interactions with the SMCHD1-containing
fragment were also recorded in Hi-C data) and with the
adjacent 1-Mb downstream fragment on chromosome 18
(positions 3,000,000–3,999,999; 663 interactions). On a
100-kb scale, the SMCHD1 gene was found to occupy two
consecutive fragments (fragment 1: 2,600,000–2,699,999
and fragment 2: 2,700,000–2,799,999, Fig. 1); for each of
these fragments, the number of intra-chromosomal inter-
actions was also available from the Hi-C data. Fragment 1
and fragment 2 interacted most strongly with them-
selves (256 and 237 interactions, respectively) whereas
the number of interactions with other 100-kb fragments
on chromosome 18 did not exceed 30. The ENCODE
data indicated the presence of two weak CTCF-binding
sites (scores <445/1000) between positions 2,531,952
and 2,537,783 and a strong one (with score 719/1000)
at positions 2,922,164 and 2,922,551. Among other
functions, CTCF and its associated proteins that bind
to the CTCF-binding sites are thought to play a role in
forming barriers between regulatory regions but are also
involved (together with other transcription factors) in con-
trolling chromatin-looping interactions and structure
(reviewed in [19]) although a recent study [16] indicated
that insulator activities of CTCF could be tissue- or cell-
line-specific. Because the first CTCF-binding site was
found within the 100-kb region (2,500,000–2,599,999),
which has only 23 interactions with the SMCHD1-con-
taining region, we opted to extend the search for potential
regulatory elements to positions 2,531,952–2,922,551.
The ENCODE data on histone modification marks,
H3K4me1 and H3K27ac, available for eight cell lines, re-
veal the presence of these marks in the GM12878 cell
line between positions 2,624,475 and 2,635,775. The
ENCODE data also indicated the presence of an
H3K4me3-enriched region, characteristic of an active
promoter, somewhere between positions 2,644,486 and
2,648,785 on the interacting fragment (Fig. 1). There is a
strong enhancer at positions 2,631,000–2,632,200 and a
transcription factor binding site (TFBS)-enriched region
between positions 2,631,527 and 2,632,188; the latter re-
gion, ~14 kb upstream of the SMCHD1 gene, was se-
lected for sequencing in FSHD patients.
A second region, distal (~84 kb) to the SMCHD1 gene,
was also selected for sequencing (positions 2,561,489–
2,562,509) on the basis that it is enriched in H3K4me3
and TFBSs and corresponds to a peak of DNaseI sensi-
tivity signal, characteristic of open chromatin and an
active cis-regulatory region; it also shows a weak inter-
action with the SMCHD1-containing region. The
Fig. 1 Schematic representation of the chromosomal regions enriched in transcription factor binding sites (TFBS), histone mark H3K27ac and
DNAseI hypersensitive signal within 1-Mb-long SMCHD1-containing DNA fragments (not to scale). Two consecutive 100-kb fragments harbouring
the SMCHD1 gene are denoted as Fragments 1 and 2. CTCF is a binding site for the insulator protein
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ENCODE data on histone modification marks H3K4me1
and H3K27ac revealed the presence of these marks in
eight cell lines, the exception being GM12878, between
positions 2,557,575 and 2,566,775. ChromHMM track
indicated the presence of an active promoter at positions
2,560,200–2,563,800, which corresponds precisely to the
METTL4 gene promoter.
Search for sequence variants within the potential
remotely acting regulatory regions of SMCHD1
The two predicted regions, respectively ~14 kb and ~85 kb
upstream of the SMCHD1 gene, were sequenced in 229
FSHD patients of Central European descent (the DNA-
sequencing procedure is described in the Additional file 1;
the primers used are given in Table S1). DNA sequence data
from these regions, derived from the 1000 Genomes Project,
are available for 226 individuals from the CEU (Utah Resi-
dents with Northern and Western European Ancestry)
population and were used as controls.
In addition, DNA from the parents of the FSHD probands,
from families 1 and 2, was analysed. Family 1 was referred to
us because the proband exhibited facial and shoulder girdle
weakness; both parents were healthy. In family 2, the pro-
band had early onset FSHD, the parents of the proband were
healthy and non-consanguineous and no other member of
the family was affected with FSHD. Neither parent showed
any evidence of facial or other muscle weakness.
We identified variants in the region proximal (~14 kb
upstream) to the SMCHD1 gene in two probands from
families 1 and 2. These variants were not present in
dbSNP (http://www.ncbi.nlm.nih.gov/snp) or the 1000
Genomes Project data. The two variants, NCBI36/hg18:
chr18:2,631,610 T > C and NCBI36/hg18:chr18:2,631,886
G > A, were found in probands from families 1 and 2,
respectively (Figs. 2 and 3). They were also identified in
the clinically unaffected mothers of these two patients.
Variant NCBI36/hg18:chr18:2,631,610 T >C was found in
the proband who was originally tested due to facial and
shoulder girdle muscle weakness. All three members of this
family (family 1) were found to harbour >11 D4Z4 repeats,
but only the proband was symptomatic. No mutations
within the SMCHD1-coding region were detected. Both the
proband and the unaffected mother harboured the heterozy-
gous sequence change NCBI36/hg18:chr18:2,631,610 T >C.
This nucleotide is conserved in primates (human, chimpan-
zee, gorilla, orang-utan, gibbon, rhesus monkey, crab-eating
macaque, baboon, green monkey and squirrel monkey); the
evolutionary conservation score, phyloP [20], calculated
across 44 vertebrates, was 0.557, indicating a conserved
nucleotide.
The second novel sequence change, NCBI36/hg18:
2,631,886 G >A, was found in the proband from family 2.
Molecular testing based on EcoRI/BlnI analysis [10] iden-
tified two intact D4Z4 repeats in the proband and >11 in
the mother. Interestingly, his unaffected mother was a
mosaic for this change (Fig. 3). This nucleotide is con-
served in primates (human, chimpanzee, orang-utan, rhe-
sus monkey, baboon and marmoset). The evolutionary
conservation score across 44 vertebrate species was 0.431.
As the proband in this family has FSHD1, it is possible
that this sequence variant could modify the clinical ex-
pression of FSHD1 as this patient exhibited weakness of
facial and shoulder girdle muscle with early onset (8 years
of age).
The third heterozygous sequence variant was found in
the region proximal (~14 kb upstream) to the SMCHD1
gene at position NCBI36/hg18:2,631,858; a surprisingly
high proportion (182/229) of patients were found to have
a C-allele at this position with 47/229 patients having a T-
allele. A T/C polymorphism at this position is recorded in
dbSNP (rs7229070) with C being the minor allele with
MAF= 0.30 for a CEU (Utah Residents with Northern and
Western European Ancestry) population (226 genomes)
sequenced by the 1000 Genomes Project. According to
dbSNP, the clinical significance of this SNP is unknown.
This polymorphism occurs in a region which is evolution-
arily conserved among primates; all the other primate spe-
cies examined have nucleotide T in this position in their
wild-type sequences. In addition, this nucleotide is also
conserved in members of other mammalian orders includ-
ing the artiodactyla, rodentia and carnivora (phyloP score
across 44 vertebrate species is 0.691).
All three sequence changes, 2,631,610 T > C, 2,631,858
T > C and 2,631,886 G > A, occur in close proximity to,
or within, the DNaseI hypersensitive cluster (positions
2,631,700–2,631,930) characterized by a high score (976
out of 1000) that corresponds to an open chromatin do-
main and rich in TFBSs (IRF1, STAT1, STAT2, RUNX3,
BATF, SPI1) with IRF1 (positions 2,631,639–2,632,023),
STAT1 (2,631,540–2,632,016), STAT2 (2,631,654–
2,632,010) and RUNX3 (2,631,672–2,631,955) transcrip-
tion factor binding sites having the highest score (1000/
1000). All three sequence variants also occur in a region
enriched in enhancer-associated marks, H3K4me1 and
H3K27ac, observed in cell line GM12878.
Recently published data on looping interactions [15] re-
veal a strong looping interaction in the GM12878 cell line,
between a 5-kb fragment corresponding to the promoter
region of the SMCHD1 gene (positions 2,640,000–
2,645,000) and a 5-kb region (positions 2,630,000–
2,635,000) harbouring the three variants found (note that
all positions were ‘lifted over’ to the hg18 assembly). It
was not possible to confirm the existence of a looping
interaction between the SMCHD1 gene promoter and the
region ~14 kb upstream of the gene harbouring the vari-
ants using Capture Hi-C data [16] since only interactions
between promoters and interacting fragments separated
by >20 kb were reported.
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Methylation analysis of families 1 and 2
The SMCHD1 protein plays a role in the methylation of
large chromosomal regions, including the X chromo-
some and the D4Z4 array. It is required for the mainten-
ance of X inactivation in females and hypermethylation
of CpG islands associated with the inactive X chromo-
some. Loss of SMCHD1 activity in FSHD2 patients re-
duces methylation of the D4Z4 array, allowing the
transcriptional machinery to gain access to the DUX4
gene [5]. FSHD2 is caused by the co-inheritance of two
independent events: an FSHD-permissive chromosome 4
haplotype (necessary for the polyadenylation of DUX4
mRNA) and a variant in SMCHD1 [5]. SMCHD1 regu-
lates chromatin repression in a wide variety of different
organisms. Given the wider role of SMCHD1 in regulat-
ing methylation, it may be that SMCHD1 serves as a
modifier in human genetic disease [9–11].
Hartweck et al. [21] identified an extreme demethyla-
tion of region DR1 within the D4Z4 repeat and demon-
strated that this region is hypomethylated in the
majority of FSHD2 patients. On the basis of this finding,
the methylation of this region was measured in blood
samples from members of families 1 and 2 using bisul-
phite conversion followed by pyrosequencing; the ratios
of C vs. T at each of the ten statistically validated sites
within the DR1 region were averaged (see Additional
file 1). The proband from family 2 has two D4Z4 repeat
units and exhibits a methylation level of 24 %, compatible
with the methylation level seen in FSHD2 patients [5].
The clinically unaffected mother of this patient was a mo-
saic for the variant, but her D4Z4 repeat was not hypo-
methylated. Based on a two D4Z4 unit array combined
with the 4qA haplotype, hypomethylation and
evolutionary conservation, we propose that the promoter
a b
Fig. 3 Pedigree (a) and mutation (b) in the proximal promoter region of the SMCHD1 gene, family 2
a b
Fig. 2 Pedigree (a) and mutation (b) in the proximal promoter region of the SMCHD1 gene, family 1
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variant in SMCHD1 (2,631,886 G >A) represents a plaus-
ible candidate for modifying the expression of FSHD1 in
this patient.
The results of methylation analysis for the proband
from family 1 were inconclusive; no hypomethylation of
D4Z4 was observed in the DR1 region, but other regions
(DR2 and DR3) were not tested. Based on an epigenetic
signature, Jones et al. [22] have developed a new labora-
tory test that identifies symptomatic FSHD1 and 2 from
non-penetrant FSHD carriers and other muscular dys-
trophies. In a recent study, Huichalaf et al. [23] have
shown that DNA methylation does not correlate with
the density of CpG dinucleotides within D4Z4. However,
DNA methylation and histone de-acetylation are re-
quired to maintain the repression of the FSHD candidate
gene. H3K27me3 was reported to be enriched at D4Z4
in healthy subjects and significantly decreased in FSHD
patients. Further functional ascertainment will be re-
quired in order to establish the pathological significance
of the variants identified in our study.
Methylation plays an important role in the marked
clinical variability seen in FSHD patients. Recent studies
indicate that a combination of genetic and epigenetic
factors act on the D4Z4 repeat array to determine the
probability of DUX4 expression in the skeletal muscle
and influence disease penetrance and progression [24].
In FSHD patients harbouring 1 to 6 D4Z4 units, the
D4Z4 unit number appears to correlate inversely with
the severity of the disease, but in patients with 7–10
D4Z4 units, severity depends upon the factors that regu-
late methylation [8]. In a family with a case of full-blown
FSHD and a relative with a non-penetrant mutation
bearing an identical number of D4Z4 units, the differ-
ence in clinical severity between these two family
members appears to be due to methylation [8].
In FSHD2, the mutations that disrupt the open reading
frame are believed to result in SMCHD1 haploinsuffi-
ciency and to have less effect on D4Z4 methylation than
mutations which maintain the SMCHD1 open reading
frame, possibly acting through a dominant negative
mechanism [8]. These new developments are improving
our understanding of the pathology of FSHD and
emphasize the potential for combinatorial effects of gen-
etic and epigenetic factors in influencing the onset and
progression of the disease.
Conclusions
In this study, we propose an improved (as compared to
the previously described [25]) approach for predicting
the possible location of remotely acting regulatory ele-
ments that might influence the transcriptional regulation
of their associated gene(s). This approach was success-
fully employed in the context of the in silico prediction
of potential remotely acting regulatory elements for the
SMCHD1 gene. Subsequent sequencing of these pre-
dicted regions identified three sequence variants in
FSHD patients which represent candidate variants of po-
tential functional significance.
This approach demonstrates a novel means to screen
for disease-relevant mutations that reside beyond the
immediate vicinity of a given disease gene. It therefore
promises not only to be useful in investigating disorders
in which mutations may occur in remotely acting regula-
tory elements but also in identifying the causative non-
coding mutations found by GWAS that are often distant
from their target genes.
Methods
Long-range interaction data (Hi-C)
In December 2013, when this study commenced, the in-
ter- and intra-chromosomal interaction data were avail-
able for, respectively, 1-Mb and 100-kb fragments from
the human GM06990 lymphoblastoid cell line. These
data were obtained by means of the chromosome con-
formation capture technique [14] and were available at
www.ncbi.nlm.nih.gov/geo/ (accession number GSE18
199). Data, recently obtained using in situ Hi-C method
[15] at a 1-kb resolution, together with Capture Hi-C
data on looping interactions for ~22,000 promoters [16],
were used to validate the initial results.
Epigenetic features, transcription factor binding sites
and enhancers
Data on the occurrence and the strength of DNaseI
hypersensitive sites, the occurrence and level of enrich-
ment in the H3k4me1, H3k4me3 and H3k27ac methyla-
tion marks, assayed using various biochemical techniques,
were downloaded from the ENCODE database ([26];
http://genome.ucsc.edu/index.html).
Genomic positions of 55 transcription factor binding
sites (TFBSs), including an insulator CTCF-binding site, all
assayed by ChIP-seq, were also downloaded from the EN-
CODE database. Genomic positions of active enhancers
assayed using CAGE techniques were downloaded from
the FANTOM (http://fantom.gsc.riken.jp/5/; [27]) and
ENCODE (ChromHMM track) databases. It should be
noted that biochemical assays used to map these func-
tional elements usually capture extended DNA regions,
often spanning several hundred base pairs, making it diffi-
cult to define the exact boundaries of functional elements.
In cases where data were available from multiple cell
lines, the data for the karyotypically normal human lym-
phoblastoid cell line GM06990 were used. The choice of
this cell line was predicated upon the availability of Hi-C
data for this particular cell line. Data on H3k4me1 and
H3K27ac methylation marks were not available for the
GM06990 cell line; data for the GM12878 cell line were
used instead.
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Where necessary, all positions were ‘lifted over’ to
the hg18 assembly using the Lift Genome Annotation
program available at https://genome.ucsc.edu/cgi-bin/
hgLiftOver.
In silico prediction of possible remotely acting regulatory
regions and sites of mutation
To identify possible remotely acting regulatory regions
and the sites of mutation within these regions, the
following step-by-step procedure was adopted:
Step 1. Set the size of the fragment to 1 Mb or 100 kb.
Step 2. Use Hi-C data to find a fragment (bin) that
harbours the gene/gene promoter in question,
henceforth termed a gene-containing fragment.
Step 3. Use Hi-C data to find a fragment(s) with
the highest number of interactions with the
gene-containing fragment, henceforth termed
an interacting fragment(s).
Step 4. Use ENCODE data to identify the location(s)
of CTCF-binding sites within the interacting fragment.
Refine the interacting fragment(s) to shorter regions
bounded by the CTCF-binding site. If the interacting
fragment is found upstream of the gene, a DNA
fragment between the CTCF-binding site and the
gene in question is considered as a region possibly
harbouring remotely acting regulatory element(s).
If the interacting fragment is found downstream of
the gene, a DNA fragment between the gene and the
CTCF-binding site is considered as a region possibly
harbouring remotely acting regulatory element(s).
Step 5. Use the ENCODE and FANTOM data on the
occurrence of epigenetic marks, enhancers, etc., to
further refine regions possibly harbouring remotely
acting regulatory element(s) by identifying shorter
regions enriched in histone modification marks
(H3K4me1, H3K27ac, H3K4me3) and transcription
factor binding sites and corresponding to peaks of
DNaseI hypersensitivity signal.
Step 6. Validate regions found using in situ and
Capture Hi-C data.
The SMCHD1 gene and clinical data
The SMCHD1 gene, encoding the structural mainten-
ance of chromosomes’ flexible hinge domain-containing
protein 1, occupies positions 2,645,885–2,795,015 on
chromosome 18 (NCBI build 37, UCSC hg18 and
Ensembl GRCh37).
Of the 229 FSHD patients analysed in this study, 29
had >11 D4Z4 repeat units whereas 2 of these patients
harboured novel FSHD-causing (or disease-modifying)
sequence variants in the SMCHD1 gene identified in
FSHD patients by Winston et al. [10] that could modu-
late the expression of FSHD1.
DNA sequencing and methylation analysis
The DNA from patients was digested with EcoRI and BlnI,
size-fractionated by electrophoresis, Southern blotted and
hybridized with DNA marker p13E11 [1]; sequencing was
performed as described in Additional file 1. Methylation
quantification was performed as described by Hartweck et
al. [21]; see Additional file 1 for details.
Additional file
Additional file 1: Summary of experimental procedures used. A
brief description of DNA sequencing and methylation analysis used in
this study.
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